Korro Bio expects to soon initiate a phase 1/2 study, using KRRO-110 for the treatment of patients with Alpha-1 Antitrypsin Deficiency, with data to be released 2nd half of 2024. Interim analysis from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback